![Hatice Bölek: Does treatment sequencing with cabazitaxel and 177Lu-PSMA-617 impact outcomes in mCRPC?](https://oncodaily.com/pub/uploads/2025/01/7d2aa3b915964a6890a45a1da3c1a194-1.jpg)
Hatice Bölek/X
Jan 10, 2025, 19:44
Hatice Bölek: Does treatment sequencing with cabazitaxel and 177Lu-PSMA-617 impact outcomes in mCRPC?
Hatice Bölek, Medical Oncologist at Ankara University School of Medicine, shared a recent article on X:
“Does treatment sequencing with cabazitaxel and 177Lu-PSMA-617 impact outcomes in mCRPC?
No difference in PFS2 and OS between treatment sequences.”
Authors: Hatice Bolek, Satı Coskun Yazgan, Furkan Ceylan, Jorge Esteban-Villarrubia, Cagatay Arslan, Tülay Kuş, Deniz Tural, Mehmet Ali Nahit Sendur, Nuriye Ozlem Kucuk, Elif Çıngı Özdemir, Elena Castro, Emre Yekedüz and Yüksel Ürün
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 9, 2025, 18:29
Feb 9, 2025, 18:21
Feb 9, 2025, 18:09
Feb 9, 2025, 18:06
Feb 9, 2025, 17:54
Feb 9, 2025, 17:24
Feb 9, 2025, 17:14